The market correction for stocks related to electromobility, hydrogen and fuel cell technology continued to gain momentum in recent weeks. However, First Hydrogen (ISIN:CA32057N1042) was able to escape this. Since the publication of our initial report at the end of December '21, the share price has increased by around 63%. In addition to the positive share price performance, the Company has also shone on a fundamental level. For example, First Hydrogen is making good progress with the market launch of hydrogen filling stations. In addition, the quality of the management staff was significantly increased in order to achieve the targets.
Digitalization is one of the most important social and economic developments of our time. Companies face the challenge of rethinking business operations and processes with the help of existing digital technologies, such as the Internet of Things, blockchain or artificial intelligence, and in some cases implementing radically new processes. While many projects fail, the transition from the analog industrial age to knowledge and creativity shaped by digital technologies and digital innovations offers opportunities to establish new, highly scalable business models. In 2015, the former publishing house Aspermont started its digital transformation by building a unique platform technology. This transformation was completed last year. Since then, the expansion phase has been gaining momentum. The opportunities for the Australian company are enormous but have hardly been noticed by the market yet.
The Canadian gold explorer had an impressive start to the new year by reaching a milestone. The Company has one of the largest non-producing land areas in West Africa. Located in Mali, Africa's third-largest gold producer, the project has enormous development potential. The right course has been set. It is just a matter of when, not if, the Company will reevaluate. Furthermore, the Canadians are increasingly a potential takeover candidate.
Humanity is still caught up in the covid pandemic. The shares of vaccine manufacturers have skyrocketed. Despite great successes in combating the pandemic, there are also downsides. These are secondary damages, such as damage to the heart. This is where the Canadian company Cardiol Therapeutics comes in. The company is currently undergoing promising clinical trials with preparations based on cannabidiol that are intended to treat inflammatory heart disease. Recent research shows that cannabis ingredients can prevent infection with the Corona virus by blocking its entry into cells. This suggests that Cardiol’s preparations could have blockbuster potential. Analysts unanimously believe that the shares, which are also listed on the NASDAQ, have the potential to multiply.
wallstreet:online AG has presented an interim report for the past year. It clearly shows what already became clear in the Report 2021 a discrepancy in the company valuation compared to the peer group. The number of securities accounts and the assets under management could now be more than doubled compared to the previous year. According to the data, the company is the largest neobroker operator in Germany, with EUR 8.8 billion in assets under custody.
Hydrogen is the ultimate future topic and is not only revolutionizing the automotive industry. The topic is becoming explosive because e-mobility cannot solve all the problems of the future and cannot be used in many areas. With its specification, hydrogen is also reaching air, rail and shipping traffic and is thus coming more into the focus of science. Will it be the topic for 2022? The opportunity for investors is favorable as governments around the world declare climate protection budgets. Germany and France plan to jointly invest tens of billions in transforming their industries. Norwegian H2 specialist Nel ASA is one of the European pioneers in electrolyzer technology. But what are the opportunities for investors in 2022 after a 300% increase since 2018? A look at the overall market and specifically at the stock.
Achieving the energy transition is at the top of the political agenda, at least in Germany. One of the biggest challenges here is to achieve climate neutrality in the transport sector by 2045. After all, according to the Federal Environment Agency, the sector is responsible for around 20% of total greenhouse gas emissions. In contrast to the energy sector or industry, CO2 emissions have even increased since 1990 despite the development of more efficient vehicles. Therefore, significant changes are needed to reverse emissions growth and meet new mandates while meeting the increasing demand for mobility and freight. In the passenger vehicle sector, both the automotive industry and policymakers are focusing on battery technology. In contrast, hydrogen fuel cell technology offers clear advantages over electric propulsion for commercial vehicles, which are responsible for about 35% of transportation emissions. First Hydrogen aims to become the leading designer and manufacturer of zero-emission, long-range hydrogen-powered vehicles in the UK, EU and North America. The conditions for this are favorable. That is why we are taking a closer look at this exciting market.
Vaccines against cancer and improved transport of active substances into tumor cells - the Canadian biotech company Defence Therapeutics promises no less with its patented technology. In the next six months, Defence Therapeutics intends to prove that its vaccines are safe in Phase 1 trials. That finding could be a liberating blow for the company. Read our research to find out what else makes the biotech tick and why the stock is entering an exciting phase.
We are in the middle of the fourth Corona wave. Uncertainty about the effects of the new mutation Omicron recently weighed on the mood on the stock markets. Skeptical statements by Moderna's CEO on the controllability of the new variant are irritating, especially since BioNTech has an entirely different view of the situation. This uncertainty hit Valneva, a new Corona vaccine supplier looking to throw its hat into the ring, particularly hard. Shares in the French-Austrian biotech company lost significant ground after - at first glance - disappointing results on the suitability of their vaccine as a booster vaccine. Valneva's approach with so-called dead vaccines contrasts with vector or mRNA vaccines, which are currently exclusively used. Dead vaccines have been used in medicine for a long time (tetanus, pertussis, diphtheria, influenza vaccination) and are considered well-established. The new vaccine category could thus persuade vaccine skeptics to get vaccinated. Approval of the Valneva vaccine in the EU has been applied for, and initial orders have been received. The green light from the health authorities should come soon. US-based Novavax should be even quicker to market with a protein vaccine. What chances do the newcomers have? Are they the new top dogs?
Early-stage biotech companies rarely provide detailed insights into their universe. It is not surprising, as the market for diagnostics in the context of Covid-19, in particular, is highly competitive. The company featured here, XPhyto Therapeutics Corp. is reportedly preparing to take off in the coming weeks and months in not one but two of three business areas. Specifically, it is looking at precise and rapid PCR testing that does not require a traditional lab and promises results in 25 minutes. But it is also about testing methods for other typical diseases. Regarding medications, the provider presented here is working on procedures to improve their effect on patients and even produce them more cheaply. The following report on biotech summarizes which company XPhyto wants to catch up with in the long term and the market potential. An insight into a very dynamic market.